Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 [Breast Cancer]

Conclusion The 21-gene RS is independently prognostic for both TTP and 2-year OS in ER–positive/HER2-negative de novo stage IV breast cancer. Prospective validation is needed to determine the potential role for this assay in the clinical management of this patient subset.

http://jco.ascopubs.org/cgi/content/short/34/20/2359?rss=1

Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: King, Lyman, Gonen, Voci, De Brot, Boafo, Sing, Hwang, Alvarado, Liu, Boughey, McGuire, Van Poznak, Jacobs, Meszoely, Krontiras, Babiera, Norton, Morrow, Hudis Tags: Diagnosis & Staging, Surgery Breast Cancer Source Type: research